Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVENT
- Development stage
- Preclinical
- Lead developer
- Avesthagen
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
AVENT is an etanercept biosimilar developed by Avestha Gengraine Technologies (Avesthagen). It is a recombinant fusion protein consisting of the extracellular ligand-binding portion of the human 75 kDa (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. AVENT acts as a TNF-alpha decoy, binding to and neutralizing circulating tumor necrosis factor-alpha (TNF-alpha), thereby preventing its interaction with cell surface TNF receptors. This mechanism effectively reduces the inflammatory response associated with autoimmune disorders. The drug is primarily targeted for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis. It has completed preclinical toxicity and efficacy studies, demonstrating high structural and functional similarity to the reference biologic, etanercept.
- Brand names
- AVENT
- Other names
- Etanercept biosimilarTNF-alpha decoyTNF receptor-Fc fusion protein
02
Targets
LTA (Lymphotoxin-alpha)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on AVENT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVENT.